Brii Biosciences was among the participants in a series A round for infectious disease drug developer AN2 and has secured Chinese commercialisation rights for the startup's lead asset.
US-based infectious-disease treatment developer AN2 Therapeutics has emerged from stealth with $12m of series A funding from investors including medicine provider Brii Biosciences.
The round was led by investment firm Mountain Group Partners and also featured life sciences-focused investment fund Adjuvant Capital and venture capital fund BioRock Ventures.
AN2 is working on antibacterial drugs targeting previously unexploited biological mechanisms to control outbreaks of infectious disease more effectively than existing medications. The series A funds will help advance clinical development of…
